Dear Colleague,

It is my pleasure to invite you to this Vifor Fresenius Medical Care Renal Pharma-sponsored educational symposium at ERA-EDTA 2019, entitled ‘Navigating CKD-MBD in 2019: expert perspectives’.

The majority of patients suffering from chronic kidney disease (CKD) are affected by mineral and bone disorders (MBD). Abnormalities in CKD-MBD parameters, for example serum phosphate, calcium, parathyroid hormone, vitamin D and fibroblast growth factor-23, among others, have been associated with cardiovascular and bone disease, leading to increased morbidity and mortality. Thus, conditions such as hyperphosphataemia and secondary hyperparathyroidism (SHPT) are established areas for medical intervention, albeit ones associated with numerous complexities and controversies.

During this educational symposium we will initially address the pathogenesis of SHPT and review contemporary approaches to its management in both the pre-dialysis and dialysis settings. The second presentation will then consider the challenges associated with hyperphosphataemia management, including appropriate phosphate targets and current and future strategies that may help patients achieve them.

I am confident that this symposium will enhance your understanding of this challenging syndrome, and I look forward to seeing you there.

Professor Jordi Bover
Chair

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic. Payment has been made to the congress organiser to hold the symposium and refreshments have been provided by the company.